Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
暂无分享,去创建一个
T. Puthanakit | T. Chotpitayasunondh | J. Sophonphan | W. Phongsamart | C. Techasaensiri | P. Suntarattiwong | A. Tangsathapornpong | D. Suwanpakdee | N. Chantasrisawad | Peera Jaruampornpan
[1] G. Alter,et al. Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children , 2022, medRxiv.
[2] G. Alter,et al. Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals , 2021, The Journal of infectious diseases.
[3] William F. Fadel,et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[4] T. Puthanakit,et al. Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand , 2021, IJID Regions.
[5] B. Bell,et al. The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[6] Robin L. Jones,et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.
[7] Y. Kreiss,et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.
[8] B. Salzberger,et al. Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2 , 2021, Vaccines.
[9] E. Ingulli,et al. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients , 2021, Pediatric Nephrology.
[10] K. Syrigos,et al. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection , 2021, Vaccines.
[11] Gregory F. Wu,et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, Annals of Internal Medicine.
[12] H. Samji,et al. Review: Mental health impacts of the COVID‐19 pandemic on children and youth – a systematic review , 2021, Child and adolescent mental health.
[13] C. Broder,et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers , 2021, medRxiv.
[14] S. Fourati,et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients , 2021, The Lancet.
[15] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[16] G. Shefer,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.
[17] Manish M Patel,et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 , 2021, JAMA network open.
[18] P. Dormitzer,et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.
[19] D. Segev,et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.
[20] D. Segev,et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. , 2021, JAMA.
[21] D. Yahav,et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study , 2021, Clinical Microbiology and Infection.
[22] A. Huppert,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 , 2021, Clinical Microbiology and Infection.
[23] D. Schwartz,et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus , 2021, American Journal of Transplantation.
[24] S. Dominguez,et al. Risk Factors for Severe COVID-19 in Children. , 2021, The Pediatric infectious disease journal.
[25] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[26] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[27] Deblina Roy,et al. Impact of COVID-19 and lockdown on mental health of children and adolescents: A narrative review with recommendations , 2020, Psychiatry Research.
[28] M. Chen,et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.
[29] Ansel Hoang,et al. COVID-19 in 7780 pediatric patients: A systematic review , 2020, EClinicalMedicine.